ানোSanofi: New analysis of Nirsevimab data supports its effectiveness against RSV MyPharma version

Posted on Wednesday, May 11, 2022 Sanofi announced that the results of a pre-determined analysis of data pooled from the Pivotal Phase III Melody Trial and the Nirsevimab Phase IIb Trial showed an efficacy of 79.5% (95 CI: 65.9 to 87.7) (relative risk reduction compared to placebo);

Artificial Intelligence: Expcientia and Sanofi will collaborate to create a portfolio of perfect drugs MyPharma Editions

Posted on Friday, January 7th, 2022 Sanofi and Exscientia have announced a groundbreaking licensing and research collaboration agreement to develop 15 new small molecule candidates in oncology and immunology using the Artificial Intelligence (AI) platform. The two companies have been collaborating since 2016, and in 2019, Sanofi licensed the development of bi-specific small molecules for … Read more

Artificial Intelligence: Sanofi Invests $ 180 Million in Okin’s Capital to Advance Version of Mycology Portfolio Mypharma

Posted on Thursday, November 18, 2021 Sanofi has just announced a 180 million investment in Okin’s Capital and established a new strategic partnership for research and development programs on four forms of cancer, with an initial milestone of 90 90 million over three years, including additional milestones. Payment Owkin is an artificial intelligence (AI) and … Read more